In conclusion, the current study demonstrated that sequential abemaciclib treatment following eribulin enhanced anti-tumor activity in vitro and in vivo on the CDK4/6 inhibitor-resistant cells by more effectively inhibiting the G2/M cell cycle phase. Here, CDK4 is linked to neoplasm.